Biosearch, S.A., a biotechnology company, operates in pharmaceutical, nutraceutical, and functional food sectors worldwide.
Flawless balance sheet with reasonable growth potential.
Share Price & News
How has Biosearch's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PUL's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: PUL underperformed the German Biotechs industry which returned -5.1% over the past year.
Return vs Market: PUL underperformed the German Market which returned -17.7% over the past year.
Price Volatility Vs. Market
How volatile is Biosearch's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Biosearch undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: PUL (€0.77) is trading above our estimate of fair value (€0.38)
Significantly Below Fair Value: PUL is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: PUL is poor value based on its PE Ratio (80x) compared to the Biotechs industry average (34x).
PE vs Market: PUL is poor value based on its PE Ratio (80x) compared to the German market (16.4x).
Price to Earnings Growth Ratio
PEG Ratio: PUL is poor value based on its PEG Ratio (1.1x)
Price to Book Ratio
PB vs Industry: PUL is good value based on its PB Ratio (1.9x) compared to the DE Biotechs industry average (3.6x).
How is Biosearch forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PUL's forecast earnings growth (74.1% per year) is above the savings rate (-0.4%).
Earnings vs Market: PUL's earnings (74.1% per year) are forecast to grow faster than the German market (14.3% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: PUL's revenue (17% per year) is forecast to grow faster than the German market (4.1% per year).
High Growth Revenue: PUL's revenue (17% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PUL's Return on Equity is forecast to be low in 3 years time (16.2%).
How has Biosearch performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PUL has high quality earnings.
Growing Profit Margin: PUL's current net profit margins (2.8%) are lower than last year (12.3%).
Past Earnings Growth Analysis
Earnings Trend: PUL has become profitable over the past 5 years, growing earnings by 46.4% per year.
Accelerating Growth: PUL's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: PUL had negative earnings growth (-81%) over the past year, making it difficult to compare to the Biotechs industry average (8.7%).
Return on Equity
High ROE: PUL's Return on Equity (2.7%) is considered low.
How is Biosearch's financial position?
Financial Position Analysis
Short Term Liabilities: PUL's short term assets (€17.4M) exceed its short term liabilities (€6.0M).
Long Term Liabilities: PUL's short term assets (€17.4M) exceed its long term liabilities (€3.6M).
Debt to Equity History and Analysis
Debt Level: PUL's debt to equity ratio (18.5%) is considered satisfactory.
Reducing Debt: PUL's debt to equity ratio has reduced from 46.7% to 18.5% over the past 5 years.
Debt Coverage: PUL's debt is well covered by operating cash flow (28.4%).
Interest Coverage: PUL's interest payments on its debt are well covered by EBIT (12.3x coverage).
Inventory Level: PUL has a high level of physical assets or inventory.
Debt Coverage by Assets: PUL's debt is covered by short term assets (assets are 4x debt).
What is Biosearch's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PUL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate PUL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PUL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PUL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PUL's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
José María Roset Monrós
Mr. José María Roset Monros serves as the Chief Executive Officer of Biosearch SA (alternate name: Puleva Biotech SA) and served as its General Director. Mr. Monros served as the Chief Financial Officer of ...
|Proprietary Member of the Board of Directors||9.17yrs||€1.00k||no data|
|Independent Member of the Board of Directors||7.75yrs||€34.00k||0.071% €32.3k|
|Proprietary Member of the Board of Directors||7.75yrs||€5.00k||no data|
|Independent Member of the Board of Directors||3yrs||no data||no data|
|President of the Board of Directors||no data||no data||no data|
Experienced Board: PUL's board of directors are considered experienced (7.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.2%.
Biosearch, S.A.'s company bio, employee growth, exchange listings and data sources
- Name: Biosearch, S.A.
- Ticker: PUL
- Exchange: DB
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €45.756m
- Shares outstanding: 57.19m
- Website: https://www.biosearchlife.es
Number of Employees
- Biosearch, S.A.
- Camino de Purchil, 66
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BIO||BME (Bolsas y Mercados Espanoles)||Yes||Common Stock||ES||EUR||Dec 2001|
|0MZV||LSE (London Stock Exchange)||Yes||Common Stock||GB||EUR||Dec 2001|
|BIOE||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Common Stock||GB||EUR||Dec 2001|
|PUL||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Dec 2001|
Biosearch, S.A., a biotechnology company, operates in pharmaceutical, nutraceutical, and functional food sectors worldwide. It offers a portfolio of approximately 200 products in lipids, probiotics, and botanical extracts. The company provides a range of probiotics isolated from human breast milk under the Hereditum brand for use in infant nutrition, gastrointestinal health, and immune system and prevention of infections. It also offers various eicosapentaenoic acid and docosahexaenoic acid rich ingredients under the Eupoly-3 name, which consists of oils, emulsions, and micro-encapsulated powder for functional foods, primarily dairy products, baby foods, medical foods, and food supplements. In addition, the company provides dry, fluid, glycerinated, and soft extracts under the Exxentia name. Biosearch, S.A. is headquartered in Granada, Spain.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/30 01:04|
|End of Day Share Price||2020/03/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.